Early Hit-to-Lead ADME Screening Bundle

In vitro ADME screening during the lead optimization stage of drug discovery positively impacts drug candidate selection with an enhanced probability of success in clinical trials. Since most new drug candidates fail during preclinical and clinical development, and the late stage of the drug development cycle can be a lengthy and costly process, any means of identifying drug candidates with optimized ADME and pharmacokinetics properties in the discovery stage will have a significant impact on the drug discovery process overall.

Focused on Solutions to Address Drug Metabolism and Pharmacokinetics (DMPK) Issues and to Enable the Success of Our Clients

Our scientists provide a range of DMPK services, routinely conducting industry standard in vitro metabolism and DDI-based assays, including highly automated ADME in vitro screens. We can help drive your discovery phase structure activity relationship (SAR) by optimizing for ADME properties, in parallel to your receptor binding potency and selectivity, for more rapid identification of high quality drug candidates.

Metabolic stability, risk assessment for inhibiting key Cytochrome P450 enzymes, and cell permeability are three main early hit-to-lead ADME screening assays that all new chemical entities (NCEs) are tested for in the industry in effort to optimize key ADME properties.

About IQVIA Laboratories Bioanalytical and ADME Services

Liquid chromatography–mass spectrometry (LC/MS) and ImmunoAffinity-LC/MS services

For the quantitative determination of small molecule, peptide and macromolecule therapeutics in support of pharmacokinetic (PK) studies.

In vitro ADME assays and metabolite identification services

including permeability, metabolic stability, metabolite identification (cold & radiolabeled), and in vitro drug-drug interaction risk assessment, ranging from highly automated discovery screening platforms to definitive development studies that enable regulatory submission.

Immunoassay services

Including quantitative determination of large molecule therapeutics using ligand binding assays technologies in support of pharmacokinetic (PK) studies and immunogenicity assays assessments for pre-clinical and clinical studies including tier-based approaches, neutralizing assays, and isotyping assays.

Fit-for-purpose biomarker services

Including quantitative determination of large molecule therapeutics using ligand binding assays technologies in support of pharmacokinetic (PK) studies and immunogenicity assays assessments for pre-clinical and clinical studies including tier based approaches, neutralizing assays, and isotyping assays.